Home > Insider Trading > Filing (0001127602-22-014446)

Filing Details

Accession Number:: 0001127602-22-014446
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-05-13 16:42:41
Reporting Period:: 2022-05-11

Accepted Time:: 2022-05-13 16:42:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1682852	Moderna Inc.	MRNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1443340	Stephane Bancel	C/O Moderna, Inc. 200 Technology Square Cambridge MA 02139	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-05-11	1,473	$123.43	5,403,062	No	4	S	Direct
Common Stock	Disposition	2022-05-11	1,239	$124.32	5,401,823	No	4	S	Direct
Common Stock	Disposition	2022-05-11	1,688	$125.47	5,400,135	No	4	S	Direct
Common Stock	Disposition	2022-05-11	496	$126.35	5,399,639	No	4	S	Direct
Common Stock	Disposition	2022-05-11	421	$127.30	5,399,218	No	4	S	Direct
Common Stock	Disposition	2022-05-11	865	$128.64	5,398,353	No	4	S	Direct
Common Stock	Disposition	2022-05-11	1,186	$129.60	5,397,167	No	4	S	Direct
Common Stock	Disposition	2022-05-11	806	$130.89	5,396,361	No	4	S	Direct
Common Stock	Disposition	2022-05-11	485	$132.23	5,395,876	No	4	S	Direct
Common Stock	Disposition	2022-05-11	169	$133.24	5,395,707	No	4	S	Direct
Common Stock	Disposition	2022-05-11	172	$134.52	5,395,535	No	4	S	Direct
Common Stock	Disposition	2022-05-11	4,000	$0.00	5,391,535	No	5	G	Direct
Common Stock	Disposition	2022-05-12	10,000	$121.10	6,894,880	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	5	G	Direct
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	9,050,372	Indirect	See Footnote

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.90 to $123.88. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.92 to $124.83. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.98 to $125.98. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.00 to $126.65. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.03 to $127.60. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.11 to $129.09. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.26 to $130.18. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.32 to $131.25. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.76 to $132.71. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.91 to $133.53. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.30 to $134.72. Full information regarding the number of shares sold at each separate price can befurnished to the SEC staff upon request.
The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended May 13, 2021.
The reported disposition represents a bona fide charitable gift made by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.
These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of thesesecurities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.